Technical Analysis for RYTM - Rhythm Pharmaceuticals, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Up | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Multiple of Ten Bearish | Other | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| MACD Bearish Signal Line Cross | Bearish | -1.02% | |
| Multiple of Ten Bearish | Other | -1.02% | |
| Wide Bands | Range Expansion | -1.02% | |
| 20 DMA Support | Bullish | 1.47% | |
| Wide Bands | Range Expansion | 1.47% | |
| Gapped Up | Strength | 1.47% | |
| Multiple of Ten Bearish | Other | 5.57% | |
| Wide Bands | Range Expansion | 5.57% |
| Alert | Time |
|---|---|
| Down 3% | about 17 hours ago |
| 60 Minute Opening Range Breakdown | about 18 hours ago |
| Down 2 % | about 18 hours ago |
| Up 1% | about 21 hours ago |
| 60 Minute Opening Range Breakout | about 21 hours ago |
Get a Trading Sidekick!
- Earnings date: 11/05/2024
Rhythm Pharmaceuticals, Inc. Description
Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of peptide therapeutics for the treatment of rare genetic deficiencies that result in life-threatening metabolic disorders. The Company’s lead peptide product candidate is setmelanotide, a potent, first-in-class melanocortin-4 receptor, or MC4R, agonist for the treatment of rare genetic disorders of obesity. Setmelanotide serves as replacement therapy for the treatment of melanocortin-4, or MC4, pathway deficiencies. MC4 pathway deficiencies result in the disruption of satiety signals and energy homeostasis in the body, which, in turn, leads to intense feelings of hunger and to obesity. The Company also focused on obesity related to six single gene-related, or monogenic, MC4 pathway deficiencies pro-opiomelanocortin, or POMC, leptin receptor, or LepR, Bardet-Biedl syndrome, Alstrom syndrome, POMC heterozygous, and POMC epigenetic disorders.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Organ Systems Obesity Peptides Peptide Hormones Metabolic Disorders Monogenic Genetic Disorder Leptin Melanocortin
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 68.58 |
| 52 Week Low | 31.525 |
| Average Volume | 527,294 |
| 200-Day Moving Average | 45.70 |
| 50-Day Moving Average | 52.94 |
| 20-Day Moving Average | 56.51 |
| 10-Day Moving Average | 61.48 |
| Average True Range | 2.98 |
| RSI (14) | 56.52 |
| ADX | 24.26 |
| +DI | 29.65 |
| -DI | 21.92 |
| Chandelier Exit (Long, 3 ATRs) | 59.65 |
| Chandelier Exit (Short, 3 ATRs) | 56.54 |
| Upper Bollinger Bands | 69.15 |
| Lower Bollinger Band | 43.87 |
| Percent B (%b) | 0.61 |
| BandWidth | 44.73 |
| MACD Line | 2.50 |
| MACD Signal Line | 2.67 |
| MACD Histogram | -0.1651 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 63.47 | ||||
| Resistance 3 (R3) | 63.49 | 62.14 | 62.79 | ||
| Resistance 2 (R2) | 62.14 | 61.09 | 62.13 | 62.56 | |
| Resistance 1 (R1) | 60.75 | 60.45 | 60.08 | 60.73 | 62.33 |
| Pivot Point | 59.40 | 59.40 | 59.06 | 59.39 | 59.40 |
| Support 1 (S1) | 58.01 | 58.35 | 57.34 | 57.99 | 56.39 |
| Support 2 (S2) | 56.66 | 57.71 | 56.65 | 56.16 | |
| Support 3 (S3) | 55.27 | 56.66 | 55.94 | ||
| Support 4 (S4) | 55.25 |
